JP2025510539A - Ｈｅｒ－３に及びｈｅｒ－２又はｅｇｆｒのいずれかに結合する二特異性抗体 - Google Patents

Ｈｅｒ－３に及びｈｅｒ－２又はｅｇｆｒのいずれかに結合する二特異性抗体 Download PDF

Info

Publication number
JP2025510539A
JP2025510539A JP2024552041A JP2024552041A JP2025510539A JP 2025510539 A JP2025510539 A JP 2025510539A JP 2024552041 A JP2024552041 A JP 2024552041A JP 2024552041 A JP2024552041 A JP 2024552041A JP 2025510539 A JP2025510539 A JP 2025510539A
Authority
JP
Japan
Prior art keywords
domain
seq
antibody
bispecific
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510539A5 (https=
Inventor
ユージーン・ジュコフスキー
ピエール－エマニュエル・ジェラール
クリステル・ラルブレ
ラビア・エミリア
ティエリ・シャルド
アンドレ・ペレグリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2025510539A publication Critical patent/JP2025510539A/ja
Publication of JP2025510539A5 publication Critical patent/JP2025510539A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024552041A 2022-03-02 2023-03-01 Ｈｅｒ－３に及びｈｅｒ－２又はｅｇｆｒのいずれかに結合する二特異性抗体 Pending JP2025510539A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305242 2022-03-02
EP22305242.4 2022-03-02
PCT/EP2023/055243 WO2023166098A1 (en) 2022-03-02 2023-03-01 Bispecific antibodies binding to her-3 and to either her-2 or egfr

Publications (2)

Publication Number Publication Date
JP2025510539A true JP2025510539A (ja) 2025-04-15
JP2025510539A5 JP2025510539A5 (https=) 2026-02-27

Family

ID=80930221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552041A Pending JP2025510539A (ja) 2022-03-02 2023-03-01 Ｈｅｒ－３に及びｈｅｒ－２又はｅｇｆｒのいずれかに結合する二特異性抗体

Country Status (9)

Country Link
US (1) US20250282892A1 (https=)
EP (1) EP4486774A1 (https=)
JP (1) JP2025510539A (https=)
KR (1) KR20240154641A (https=)
CN (1) CN119451982A (https=)
AU (1) AU2023228330A1 (https=)
CA (1) CA3244947A1 (https=)
TW (1) TW202342538A (https=)
WO (1) WO2023166098A1 (https=)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
SG190572A1 (en) * 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2603527A1 (en) 2010-08-10 2013-06-19 Glycotope GmbH Humanized egfr antibodies
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
JP5786839B2 (ja) 2012-12-05 2015-09-30 株式会社デンソー エポキシ樹脂組成物および接着構造体の製造方法
US11421028B2 (en) * 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
AU2019412561A1 (en) 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains

Also Published As

Publication number Publication date
CN119451982A (zh) 2025-02-14
AU2023228330A1 (en) 2024-09-19
CA3244947A1 (en) 2023-09-07
KR20240154641A (ko) 2024-10-25
EP4486774A1 (en) 2025-01-08
TW202342538A (zh) 2023-11-01
WO2023166098A1 (en) 2023-09-07
US20250282892A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
JP7258556B2 (ja) Ｅｇｆｒ及びｈｅｒ２をターゲティングする二重特異性抗体
KR102361412B1 (ko) Cd38 및 pd-l1에 대한 결합 분자
CA2816519C (en) Pan-her antibody composition
US20250236682A1 (en) Antigen-binding protein comprising two fc domains and use thereof
CA3193662A1 (en) Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
US20250382386A1 (en) Anti-alk-1 antibody and use thereof
CA2966551A1 (en) Assay and method for determining cdc eliciting antibodies
WO2024184812A1 (en) Anti-cldn6 antibodies and methods of use
US20250282892A1 (en) Bispecific antibodies binding to her-3 and to either her-2 or egfr
EP4676962A1 (en) Anti-cldn6 antibodies and methods of use
EP4676960A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024184810A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
AU2024233425A1 (en) Anti-cd3 multispecific antibodies and methods of use
WO2024184811A1 (en) Anti-cd3 multispecific antibodies and methods of use
EA051954B1 (ru) Мультиспецифические антитела, которые связывают как mait, так и опухолевые клетки

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260218